Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has entered into an agreement to acquire Alkeus Pharmaceuticals, a closely held biotech firm developing gildeuretinol (ALK-001), while simultaneously pricing a $125.0 million private investment in public equity (PIPE) financing at $56.00 per share. The acquisition expands Tarsus’ pipeline into retinal diseases with ALK-001, an investigational once-daily oral therapy for Stargardt disease, one of the largest inherited retinal diseases with no FDA-approved treatment. The PIPE proceeds are designated to fund this pending acquisition and support ongoing clinical development activities.

The securities purchase agreement involves the sale of 2,098,519 shares of common stock and pre-funded warrants to purchase 133,625 shares at $55.9999 each. Barclays acted as lead placement agent, with BofA Securities and William Blair serving as co-placement agents. The financing is scheduled to close on August 7, 2026. Participation includes existing Alkeus investors such as TCGX, Bain Capital Life Sciences, and Wellington Management, alongside new and existing Tarsus investors including ADAR1 Capital Management and Sirenia Capital Management LP.

Financing Structure and Use of Proceeds

The PIPE financing structure allows Tarsus to raise capital while minimizing immediate dilution through the use of pre-funded warrants, which have an exercise price of $0.0001 per share. Management intends to use the net proceeds to fund clinical development and commercial activities, as well as for other general corporate purposes. This influx of capital coincides with the company’s announcement of a pending agreement to acquire Alkeus Pharmaceuticals, expanding its pipeline into retinal diseases with ALK-001, a therapy for Stargardt disease.

Strategic Context and Financial Position

This financing follows Tarsus’ second quarter 2026 results, where the company reported net product sales of $173.9 million, a year-over-year increase of more than 69%, driven by strong commercial execution of its lead therapy, XDEMVY. Despite reporting a net loss of $18.6 million for the quarter, Tarsus ended the period with $449.7 million in cash, cash equivalents, and marketable securities as of June 30, 2026. The additional $125.0 million in proceeds will bolster this balance sheet position as the company integrates Alkeus and advances its broader pipeline, including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention.

What the Numbers Show

The decision to execute a PIPE financing at $56.00 per share signals strong institutional confidence in Tarsus’ growth trajectory, particularly given the aggressive SG&A spending required to scale XDEMVY’s market penetration. With selling, general, and administrative expenses rising to $150.7 million in Q2 2026, the new capital injection provides a buffer against near-term cash burn while enabling long-term strategic expansion into retina care. The participation of existing Alkeus investors in the PIPE suggests alignment on valuation and strategic fit, reducing integration risk for the pending acquisition. Together with IRX-101, this acquisition is expected to expand Tarsus’ presence in retina and further strengthen one of the most compelling pipelines in eye care.

Tarsus Pharmaceuticals, Inc. announced that Chief Commercial Officer Aziz Mottiwala is departing the company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor. The leadership transition occurs as Tarsus enters its next phase of growth following the successful commercialization of XDEMVY and the acquisition of iRenix Medical, Inc., which expands its pipeline and strengthens its position as a leading eye care company.

Since joining Tarsus in 2021, Ms. Clase has played an integral role in the company's evolution from a clinical-stage organization to a commercial biopharmaceutical company. Her leadership has helped shape Tarsus’ strategy, advance its strategic priorities, and position the company for sustained long-term growth. Her appointment reflects the depth of experience across the company’s commercial leadership team and its focus on leadership development and succession planning.

Executive Commentary

Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus, highlighted the caliber of leaders at the company. He stated that Mr. Mottiwala's appointment as CEO of a public medical device company reflects his exceptional leadership and impact. Dr. Azamian noted that the transition comes at a moment of tremendous momentum for Tarsus, with XDEMVY continuing to grow and the pipeline expanding. He emphasized that Ms. Clase has played a pivotal role in building commercial capabilities and will be supported by an exceptional team of leaders.

Mr. Mottiwala expressed gratitude for the opportunity to help build one of the strongest commercial organizations in the industry. He stated that he has complete confidence in Ms. Clase and the entire commercial leadership team to continue raising the bar and leading Tarsus into its next chapter.

Corporate Overview

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. The company is advancing its pipeline to address diseases with high unmet need across eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for ocular rosacea, TP-05 for Lyme disease prevention, and IRX-101 as an ocular antiseptic.